Treatment of Pneumocystis Pneumonia (PCP)

First-Line Treatment: TMP-SMX

The American College of Oncology recommends high-dose trimethoprim-sulfamethoxazole (TMP-SMX) at 15-20 mg/kg/day of trimethoprim and 75-100 mg/kg/day of sulfamethoxazole, divided into doses every 6 hours for 14-21 days, as the first-line treatment for Pneumocystis jirovecii pneumonia 1, 2, 3
The dosing regimen for TMP-SMX is 15-20 mg/kg/day of trimethoprim with 75-100 mg/kg/day of sulfamethoxazole, divided into 4 doses given every 6 hours for 14-21 days, with a strength of evidence supporting its effectiveness 1, 2, 3
Initiate treatment promptly with TMP-SMX when PCP is suspected based on clinical presentation, even before bronchoscopy and bronchoalveolar lavage results are available, with a high strength of evidence supporting early treatment 1, 4, 5

The American College of Oncology recommends clindamycin 600 mg four times daily or 900 mg three times daily IV, plus primaquine 30 mg daily orally, as the first alternative treatment for PCP, with a moderate strength of evidence supporting its effectiveness 1, 2, 3
The American College of Oncology recommends pentamidine isethionate 4 mg/kg/day IV once daily, infused over 60-90 minutes, as the second alternative treatment for PCP, with a low strength of evidence supporting its effectiveness 2, 3
The American College of Oncology recommends atovaquone 750 mg oral suspension twice daily with food, as the third alternative treatment for PCP, with a low strength of evidence supporting its effectiveness 3

The American College of Oncology does not generally recommend adjunctive glucocorticosteroids for critical respiratory insufficiency due to PCP in non-HIV patients, with a moderate strength of evidence supporting this recommendation 1, 4, 5

A positive quantitative PCR >1450 copies/ml for P. jirovecii from BAL should trigger treatment initiation, with a high strength of evidence supporting this diagnostic criterion 1, 4, 5
Fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) is the preferred diagnostic method with 87-95% sensitivity, with a high strength of evidence supporting its use 2

All patients successfully treated for PCP require secondary prophylaxis to prevent recurrence, with a high strength of evidence supporting this recommendation 1, 4
The preferred agents for secondary prophylaxis are intermittent TMP-SMX (one double-strength tablet daily) or monthly aerosolized pentamidine, with a moderate strength of evidence supporting their effectiveness 1, 4, 2

The National Kidney Foundation recommends adding corticosteroids in patients with moderate to severe Pneumocystis pneumonia, defined by PaO₂ <70 mmHg in ambient air or alveolar gradient >35 mmHg, with high-quality evidence in kidney transplant recipients 6, 7, 8, 9
Additionally, reducing immunosuppressive medication should be considered in transplant patients, as recommended by the National Kidney Foundation 6, 7, 8, 9

The National Kidney Foundation recommends secondary prophylaxis to prevent recurrence in all patients successfully treated for Pneumocystis pneumonia, with the preferred regimen being cotrimoxazol 1 double-strength tablet (800/160 mg) daily 6, 7, 8, 9
In kidney transplant recipients, the National Kidney Foundation recommends prophylaxis for at least 6 weeks after treatment of acute rejection 6, 7, 8, 9